K Callis Duffin1, H Yeung2, J Takeshita3,4, G G Krueger1, A D Robertson5, A B Troxel4,6, D B Shin3,4,6, A S Van Voorhees3, J M Gelfand3,4. 1. Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA. 2. Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA. 3. Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 4. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 5. National Psoriasis Foundation, Portland, OR, USA. 6. Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Abstract
BACKGROUND: Treatment satisfaction among patients with moderate-to-severe psoriasis has not been studied and compared across treatments using a validated instrument. OBJECTIVES: To assess patient-reported satisfaction with systemic and phototherapy treatments for moderate-to-severe psoriasis in clinical practice and to correlate satisfaction with disease severity and quality-of-life measures. METHODS: This was a cross-sectional study of 1182 patients with moderate-to-severe psoriasis in the Dermatology Clinical Effectiveness Research Network in the U.S.A. Patients receiving either topical therapies only; monotherapy with oral systemic therapies, biologics or narrowband ultraviolet B phototherapy; or combination therapy with biologics and methotrexate completed the Treatment Satisfaction Questionnaire for Medication version II. RESULTS: Median unadjusted overall satisfaction scores were highest for patients receiving biologic monotherapies, biologic-methotrexate combinations, or phototherapy (83.3); scores were lowest for those receiving topical therapies only or acitretin (66.7). In fully adjusted models, compared with patients receiving methotrexate monotherapy, those receiving adalimumab, etanercept, ustekinumab, phototherapy or adalimumab with methotrexate had significantly higher median overall satisfaction scores by 7.2-8.3 points, while those receiving topical therapies only had significantly lower overall satisfaction by 8.9 points. Adjusted convenience scores were lowest for patients receiving topical therapies only or infliximab. Modest but significant correlations were found between the overall satisfaction subscale and both the Psoriasis Area and Severity Index (ρ = -0.36, P < 0.001) and the Dermatology Life Quality Index (ρ = -0.47, P < 0.001). CONCLUSIONS: Discernible differences were found in treatment satisfaction among therapies, particularly regarding treatment effectiveness and convenience. Further application of treatment satisfaction measures may inform treatment decisions and guideline development.
BACKGROUND: Treatment satisfaction among patients with moderate-to-severe psoriasis has not been studied and compared across treatments using a validated instrument. OBJECTIVES: To assess patient-reported satisfaction with systemic and phototherapy treatments for moderate-to-severe psoriasis in clinical practice and to correlate satisfaction with disease severity and quality-of-life measures. METHODS: This was a cross-sectional study of 1182 patients with moderate-to-severe psoriasis in the Dermatology Clinical Effectiveness Research Network in the U.S.A. Patients receiving either topical therapies only; monotherapy with oral systemic therapies, biologics or narrowband ultraviolet B phototherapy; or combination therapy with biologics and methotrexate completed the Treatment Satisfaction Questionnaire for Medication version II. RESULTS: Median unadjusted overall satisfaction scores were highest for patients receiving biologic monotherapies, biologic-methotrexate combinations, or phototherapy (83.3); scores were lowest for those receiving topical therapies only or acitretin (66.7). In fully adjusted models, compared with patients receiving methotrexate monotherapy, those receiving adalimumab, etanercept, ustekinumab, phototherapy or adalimumab with methotrexate had significantly higher median overall satisfaction scores by 7.2-8.3 points, while those receiving topical therapies only had significantly lower overall satisfaction by 8.9 points. Adjusted convenience scores were lowest for patients receiving topical therapies only or infliximab. Modest but significant correlations were found between the overall satisfaction subscale and both the Psoriasis Area and Severity Index (ρ = -0.36, P < 0.001) and the Dermatology Life Quality Index (ρ = -0.47, P < 0.001). CONCLUSIONS: Discernible differences were found in treatment satisfaction among therapies, particularly regarding treatment effectiveness and convenience. Further application of treatment satisfaction measures may inform treatment decisions and guideline development.
Authors: Tamar Nijsten; David J Margolis; Steven R Feldman; Tara Rolstad; Robert S Stern Journal: J Am Acad Dermatol Date: 2005-03 Impact factor: 11.527
Authors: Joel M Gelfand; Andrea L Neimann; Daniel B Shin; Xingmei Wang; David J Margolis; Andrea B Troxel Journal: JAMA Date: 2006-10-11 Impact factor: 56.272
Authors: Kim A Papp; Bruce Miller; Kenneth B Gordon; Ivor Caro; Paul Kwon; Peter G Compton; Craig L Leonardi Journal: J Am Acad Dermatol Date: 2006-04 Impact factor: 11.527
Authors: Ladan Afifi; Lindsey Shankle; April W Armstrong; Marc Boas; Alisha Bridges; Vivian Chiguil; Frank Doris; Kristina Callis Duffin; Eric Fielding; Roy Fleischmann; Joel M Gelfand; Matthew Kiselica; Catherine Kiselica; Brian LaFoy; John J Latella; Junko Takeshita; Sarah Truman; Marilyn T Wan; Vickie Wilkerson; Jashin J Wu; Michael P Siegel; Wilson Liao Journal: J Psoriasis Psoriatic Arthritis Date: 2017
Authors: Junko Takeshita; Kristina Callis Duffin; Daniel B Shin; Gerald G Krueger; Andrew D Robertson; Andrea B Troxel; Abby S Van Voorhees; Joel M Gelfand Journal: J Am Acad Dermatol Date: 2014-06-11 Impact factor: 11.527
Authors: Steven R Feldman; Bernard Goffe; Gary Rice; Matthew Mitchell; Mandeep Kaur; Debbie Robertson; Debra Sierka; Jeffrey A Bourret; Tamara S Evans; Alice Gottlieb Journal: Am Health Drug Benefits Date: 2016-12
Authors: Mingliang Zhang; Susan K Brenneman; Chureen T Carter; Breanna L Essoi; Kamyar Farahi; Michael P Johnson; Seina Lee; William H Olson Journal: Patient Prefer Adherence Date: 2015-06-16 Impact factor: 2.711
Authors: Sang Woong Youn; Tsen-Fang Tsai; Colin Theng; Siew-Eng Choon; Benny E Wiryadi; Antonio Pires; Weihao Tan; Min-Geol Lee Journal: Ann Dermatol Date: 2016-03-31 Impact factor: 1.444